NCT02533375View on ClinicalTrials.gov

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

September 15, 2016

Study Completion Date

July 20, 2017

Conditions
Generalized Pustular Psoriasis (GPP)AdalimumabJapanese
Interventions
DRUG

Adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous injection

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY